Opendata, web and dolomites

3D NEONET SIGNED

Drug Discovery and Delivery NEtwork for ONcology and Eye Therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 3D NEONET project word cloud

Explore the words cloud of the 3D NEONET project. It provides you a very rough idea of what is the project "3D NEONET" about.

outputs    toxicology    ongoing    tissues    lose    network    adme    commercial    driving    play    industries    nanotechnology    disorders    encompasses    net    operation    permeability    3dnet    world    countries    improvement    enhancement    diseases    international    excellence    biomaterials    million    hallmarks    neonet    iapp    biomarkers    innovative    academic    ophthalmology    3d    skills    practices    mortality    18    synergies    screens    people    mature    models    therapeutic    clinical    lifetime    assembling    vascular    drugs    roles    exchange    pivotal    enlarged    expertise    ocular    discovery    25    demographic    100mill    ucd    population    trials    interdisciplinary    age    preclinical    least    cancer    tangible    inflammation    technological    group    participation    disease    severe    forces    therapeutics    ie    treatments    global    trial    lives    scientific    co    therapies    eye    oncology    join    treat    fp7    angiogenesis    strengthen    competitiveness    vehicle    drug   

Project "3D NEONET" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN 

Organization address
address: BELFIELD
city: DUBLIN
postcode: 4
website: www.ucd.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.3dneonet.org
 Total cost 945˙000 €
 EC max contribution 945˙000 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2016
 Funding Scheme MSCA-RISE
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN IE (DUBLIN) coordinator 204˙975.00
2    OCUPHARM DIAGNOSTICS SL ES (MADRID) participant 259˙605.00
3    UNIVERSIDAD COMPLUTENSE DE MADRID ES (MADRID) participant 90˙000.00
4    ECM INGENIERIA AMBIENTAL SL ES (PALENCIA) participant 74˙250.00
5    THE QUEEN'S UNIVERSITY OF BELFAST UK (BELFAST) participant 70˙470.00
6    LABORATORIO IBERICO INTERNACIONAL DE NANOTECNOLOGIA PT (BRAGA) participant 51˙750.00
7    BLAFAR LIMITED IE (BLACKROCK DUBLIN) participant 40˙500.00
8    THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN IE (DUBLIN) participant 31˙500.00
9    NATIONAL UNIVERSITY OF IRELAND GALWAY IE (Galway) participant 27˙000.00
10    HGBEYOND MATERIALS SICENCE SL ES (SANTIAGO DE COMPOSTELA) participant 18˙000.00
11    LINKOPINGS UNIVERSITET SE (LINKOPING) participant 18˙000.00
12    XENOPAT SL ES (HOSPITALET DE LLOBREGAT) participant 18˙000.00
13    KARLSRUHER INSTITUT FUER TECHNOLOGIE DE (KARLSRUHE) participant 9˙450.00
14    UNIVERSIDAD DE VALLADOLID ES (VALLADOLID) participant 9˙000.00
15    WATERFORD INSTITUTE OF TECHNOLOGY IE (Waterford) participant 9˙000.00
16    ZECLINICS SL ES (BARCELONA) participant 9˙000.00
17    BIOREPERIA AB SE (LINKOPING) participant 4˙500.00
18    ASHLAND SPECIALTIES IRELAND LIMITED IE (Dublin) participant 0.00
19    CRESSET BIOMOLECULAR DISCOVERY LIMITED UK (LITLINGTON) participant 0.00
20    EXPERIMENTELLE PHARMAKOLOGIE UND ONKOLOGIE BERLIN-BUCH GMBH DE (BERLIN) participant 0.00
21    ICON CLINICAL RESEARCH LIMITED IE (DUBLIN) participant 0.00
22    EYECRO LLC US (OKLAHOMA CITY) partner 0.00

Map

 Project objective

Severe ocular disorders are affecting the lives of more than 100Mill people world-wide and at least 25% of the population above 70 years of age, a growing demographic group in EU. More than 8 million people lose their lives to cancer every year, making cancer a leading cause of pre-mature mortality in the world. The main hallmarks of severe eye conditions (i.e angiogenesis, inflammation and vascular permeability) play also pivotal roles in cancer, being therapeutic targets to treat both kind of diseases.

The overall goal of 3D-NEONET is the improvement of available treatments for cancer and ocular disease by enhancing drug discovery-development and delivery to targeted tissues, through advanced international co-operation between academic and non-academic partners. The interdisciplinary expertise provided by 18 partners in 7 countries encompasses among others: drug screens, ADME, toxicology, preclinical models, nanotechnology, biomaterials and clinical trials.

After the success with ongoing FP7-IAPP project 3D-NET (Drug Discovery and Development of Novel Eye Therapeutics; (www.ucd.ie/3dnet), we are assembling 3D-NEONET, this enlarged European interdisciplinary consortium that will join forces and exchange skills to enhance current therapies in oncology and ophthalmology. The 3 global objectives of 3D-NEONET are: 1- Enhance the discovery and development of novel drugs, targets and biomarkers for ophthalmology and oncology. 2- Improve the Delivery of Therapeutics for Oncology and Ophthalmology 3- Enhancement of Research, Commercial and Clinical Trial Project Management Practices in these fields.

Through participation in the program, 3D-NEONET is the vehicle for driving synergies between academic and non-academic partners leading to increased scientific and technological excellence as well as tangible innovative outputs that will strengthen the competitiveness of both the researchers and industries of the network even beyond the lifetime of the network.

 Deliverables

List of deliverables.
Exploitation of Fungal Resources in Drug Discovery and Drug Metabolism Report Documents, reports 2020-03-11 15:21:19
DMP Open Research Data Pilot 2020-03-11 15:21:19
Launch of 3D-NEONET Website and Social Media Websites, patent fillings, videos etc. 2020-03-11 15:21:19
Initiation of 3D-NEONET Secondments Other 2020-03-11 15:21:19
3D-animations to enhance awareness (Cancer and Blindness) Websites, patent fillings, videos etc. 2020-01-14 15:13:29

Take a look to the deliverables list in detail:  detailed list of 3D NEONET deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Nils Ohnesorge, Temitope Sasore, Daniel Hillary, Yolanda Alvarez, Michelle Carey, Breandán N. Kennedy
Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae
published pages: , ISSN: 1663-9812, DOI: 10.3389/fphar.2019.00508
Frontiers in Pharmacology 10 2020-03-11
2018 Rebecca Ward, Husvinee Sundaramurthi, Valeria Di Giacomo, Breandán N. Kennedy
Enhancing Understanding of the Visual Cycle by Applying CRISPR/Cas9 Gene Editing in Zebrafish
published pages: http://hdl.handl, ISSN: 2296-634X, DOI: 10.3389/fcell.2018.00037
Frontiers in Cell and Developmental Biology 6 2020-03-11
2018 K. Slater, P. S. Hoo, A. M. Buckley, J. M. Piulats, A. Villanueva, A. Portela, B. N. Kennedy
Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma
published pages: , ISSN: 0167-7659, DOI: 10.1007/s10555-018-9751-z
Cancer and Metastasis Reviews 2020-03-11
2019 Rebecca Ward, Zaheer Ali, Kayleigh Slater, Alison L. Reynolds, Lasse D. Jensen, Breandán N. Kennedy
Pharmacological restoration of visual function in a zebrafish model of von-Hippel Lindau disease
published pages: , ISSN: 0012-1606, DOI: 10.1016/j.ydbio.2019.02.008
Developmental Biology 2020-03-11
2019 BreandánN Kennedy, Andrea Cerquone Perpetuini, Justine Mathoux
The potential of small molecule brain-derived neurotrophic factor: mimetics to treat inherited retinal degeneration
published pages: 85, ISSN: 1673-5374, DOI: 10.4103/1673-5374.243711
Neural Regeneration Research 14/1 2020-03-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3D NEONET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "3D NEONET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

OPEN (2019)

Outcomes of Patients’ Evidence With Novel, Do-It-Yourself Artificial Pancreas Technology

Read More  

FUNGLASS (2019)

FUNctional GLASS

Read More  

ROVER (2020)

RELIABLE TECHNOLOGIES AND MODELS FOR VERIFIED WIRELESS BODY-CENTRIC TRANSMISSION AND LOCALIZATION

Read More